Concussion Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Concussion Market, By Assessment and Treatment

7.1.  Concussion Market, By Assessment and Treatment Type, 2020-2027

7.1.1.    Diagnosis

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Treatment

7.1.2.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global Concussion Market, Regional Estimates and Trend Forecast

8.1.  North America

8.1.1.    Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.1.2.    U.S.

8.1.3.    Rest of North America

8.1.3.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.2.  Europe

8.2.1.    Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.2.2.    UK

8.2.2.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.2.3.    France

8.2.3.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.2.4.    Rest of Europe

8.2.4.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.3.  APAC

8.3.1.    Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.3.2.    India

8.3.2.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.3.3.    China

8.3.3.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.3.4.    Japan

8.3.4.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.3.5.    Rest of APAC

8.3.5.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.4.  MEA

8.4.1.    Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.4.2.    GCC

8.4.2.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.4.3.    North Africa

8.4.3.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.4.4.    South Africa

8.4.4.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.4.5.    Rest of MEA

8.4.5.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.5.  Latin America

8.5.1.    Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.5.2.    Brazil

8.5.2.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

8.5.3.    Rest of LATAM

8.5.3.1.        Market Revenue and Forecast, By Assessment and Treatment (2016-2027)

Chapter 9.    Company Profiles

9.1.  Nihon Kohden Corporation

9.1.1.    Company Overview

9.1.2.    Product Offerings

9.1.3.    Financial Performance

9.1.4.    Recent Initiatives

9.2.  Compumedics Ltd.

9.2.1.    Company Overview

9.2.2.    Product Offerings

9.2.3.    Financial Performance

9.2.4.    Recent Initiatives

9.3.  Integra Lifesciences

9.3.1.    Company Overview

9.3.2.    Product Offerings

9.3.3.    Financial Performance

9.3.4.    Recent Initiatives

9.4.  BioDirection, Inc.

9.4.1.    Company Overview

9.4.2.    Product Offerings

9.4.3.    Financial Performance

9.4.4.    Recent Initiatives

9.5.  InfraScan, Inc.

9.5.1.    Company Overview

9.5.2.    Product Offerings

9.5.3.    Financial Performance

9.5.4.    Recent Initiatives

9.6.  Oculogica

9.6.1.    Company Overview

9.6.2.    Product Offerings

9.6.3.    Financial Performance

9.6.4.    Recent Initiatives

9.7.  Raumedic AG.

9.7.1.    Company Overview

9.7.2.    Product Offerings

9.7.3.    Financial Performance

9.7.4.    Recent Initiatives

Chapter 10.  Research Methodology

10.1.              Primary Research

10.2.              Secondary Research

10.3.              Assumptions

Chapter 11.  Appendix

11.1.              About Us

Glossary of Terms